HC Wainwright Forecasts CervoMed FY2027 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Investment analysts at HC Wainwright issued their FY2027 EPS estimates for CervoMed in a research note issued on Tuesday, March 17th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($2.30) for the year. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share.

Several other equities research analysts have also commented on the company. Brookline Capital Acquisition raised CervoMed to a “strong-buy” rating in a research note on Tuesday, February 3rd. Zacks Research raised CervoMed from a “strong sell” rating to a “hold” rating in a research note on Monday, January 12th. Roth Mkm cut their price target on CervoMed from $19.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday. Cantor Fitzgerald assumed coverage on shares of CervoMed in a research report on Thursday, December 18th. They set an “overweight” rating for the company. Finally, Chardan Capital lifted their price objective on shares of CervoMed from $15.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $23.00.

CervoMed Trading Down 6.4%

CRVO stock opened at $4.24 on Wednesday. The firm has a market cap of $39.26 million, a PE ratio of -1.42 and a beta of -0.77. The stock has a 50-day moving average price of $5.28 and a 200-day moving average price of $7.21. CervoMed has a 1-year low of $3.58 and a 1-year high of $16.94.

CervoMed (NASDAQ:CRVO) last issued its quarterly earnings results on Friday, March 13th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.09). CervoMed had a negative net margin of 672.80% and a negative return on equity of 96.04%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.84 million.

Institutional Trading of CervoMed

Large investors have recently made changes to their positions in the company. Rhumbline Advisers raised its stake in CervoMed by 35.5% during the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after buying an additional 1,526 shares during the period. Marshall Wace LLP acquired a new stake in CervoMed in the second quarter valued at approximately $76,000. XTX Topco Ltd acquired a new stake in CervoMed in the fourth quarter valued at approximately $81,000. Jane Street Group LLC bought a new stake in shares of CervoMed during the fourth quarter valued at approximately $88,000. Finally, GSA Capital Partners LLP bought a new stake in shares of CervoMed during the third quarter valued at approximately $91,000. 25.15% of the stock is currently owned by institutional investors and hedge funds.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.